Prothena Corp Public (PRTA) Operating Margin (2013 - 2026)
Prothena Corp Public (PRTA) recorded quarterly Operating Margin of 58.8% in Q1 2026, up 100.05% quarter-over-quarter from 115252.38% in Q4 2025, and up 237778.0% on a YoY basis from N/an in Q1 2025.
Prothena Corp Public (PRTA) Operating Margin (2013 - 2026) Analysis & Trends
Prothena Corp Public's Operating Margin history runs 14 years deep, the most recent figure standing at 58.8% for Q1 2026.
- In Q1 2026, Operating Margin rose 237778.0% year-over-year to 58.8%; the TTM figure through Mar 2026 stood at 205.43% (down 10493.0% YoY), while the FY2025 annual figure was 2216.44%, down 210208.0% from the prior year.
- Operating Margin was 58.8% for Q1 2026 at Prothena Corp Public, up from 115252.38% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 58.8% in Q1 2026 to a low of 163056.0% in Q1 2024.
- Historically, Operating Margin has averaged 19588.65% across 5 years, with a median of 2596.82% in 2023.
- The sharpest annual moves came in 2024 and 2025: Operating Margin slumped 16045918 bps in 2024, then soared 16073701 bps in 2025.
- A 5-year view of Operating Margin shows it stood at 0.14% in 2022, then plunged by 17227855 bps to 24846.52% in 2023, then jumped by 88 bps to 3056.85% in 2024, then plunged by 3670 bps to 115252.38% in 2025, then soared by 100 bps to 58.8% in 2026.
- The last three Operating Margin figures came in at 58.8% (Q1 2026), 115252.38% (Q4 2025), and 1666.25% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Prothena Corp Public | 479.08 Mn | 149.61 Mn | - | 58.80% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 58.80% |
| Dec 31, 2025 | -115,252.38% |
| Sep 30, 2025 | -1,666.25% |
| Jun 30, 2025 | -1,914.39% |
| Mar 31, 2025 | -2,318.99% |
| Dec 31, 2024 | -3,056.85% |
| Sep 30, 2024 | -6,857.01% |
| Jun 30, 2024 | 44.22% |
| Mar 31, 2024 | -163,056.00% |
| Dec 31, 2023 | -24,846.52% |
| Sep 30, 2023 | 12.15% |
| Jun 30, 2023 | -1,654.74% |
| Mar 31, 2023 | -2,596.82% |
| Dec 31, 2022 | -0.14% |
| Sep 30, 2022 | -3,317.86% |
| Jun 30, 2022 | -3,293.37% |
| Mar 31, 2022 | -3,290.89% |
| Dec 31, 2021 | -2,823.55% |
| Sep 30, 2021 | 78.48% |
| Jun 30, 2021 | 46.53% |